We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11B
AUM Growth
+$1.14B
Cap. Flow
+$217M
Cap. Flow %
1.96%
Top 10 Hldgs %
40.32%
Holding
138
New
6
Increased
33
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$152M
2
GILD icon
Gilead Sciences
GILD
+$129M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$102M
4
PBYI icon
Puma Biotechnology
PBYI
+$81.9M
5
ESRX
Express Scripts Holding Company
ESRX
+$72M

Top Sells

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$168M
2
SHPG
Shire pic
SHPG
+$85.9M
3
MCK icon
McKesson
MCK
+$66.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$66.1M
5
COO icon
Cooper Companies
COO
+$55.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Financials 0.18%
3 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADXS
101
DELISTED
Advaxis Inc
ADXS
$6.4M 0.06%
42,440
– –
CNXR
102
DELISTED
Connecture, Inc.
CNXR
$6.28M 0.06%
1,740,000
– –
ANAC
103
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$6.02M 0.05%
53,300
– –
MCRB icon
104
Seres Therapeutics
MCRB
$46.5M
$5.85M 0.05%
8,332
-4,000
-32% -$2.63M
ADAP
105
DELISTED
Adaptimmune Therapeutics
ADAP
$5.29M 0.05%
438,784
+262,314
+149% +$2.57M
RCKT icon
106
Rocket Pharmaceuticals
RCKT
$343M
$4.82M 0.04%
106,250
– –
ASND icon
107
Ascendis Pharma A/S
ASND
$16.7B
$4.07M 0.04%
222,223
– –
ROKA
108
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$3.96M 0.04%
322,043
– –
BITI
109
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$3.85M 0.03%
268,672
– –
NVTA
110
DELISTED
Invitae Corporation
NVTA
$3.75M 0.03%
456,666
– –
ALIM
111
DELISTED
Alimera Sciences
ALIM
$3.63M 0.03%
100,000
– –
PTX
112
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$3.17M 0.03%
107,300
– –
FATE icon
113
Fate Therapeutics
FATE
$270M
$2.33M 0.02%
692,900
– –
KDNY
114
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.69M 0.02%
12,000
-201,104
-94% -$27.3M
OCUL icon
115
Ocular Therapeutix
OCUL
$1.85B
$1.45M 0.01%
155,000
-53,900
-26% -$582K
BLRX
116
BioLineRX
BLRX
$12.2M
$1.35M 0.01%
1,731
– –
XTNT icon
117
Xtant Medical Holdings
XTNT
$59.7M
$1.33M 0.01%
39,620
– –
QLTI
118
DELISTED
QLT Inc
QLTI
$1.33M 0.01%
500,000
– –
CGNT
119
DELISTED
Cogentix Medical, Inc.
CGNT
$1.28M 0.01%
990,745
– –
MRTX
120
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.02M 0.01%
32,200
-207,800
-87% -$7.34M
AMRN
121
Amarin Corp
AMRN
$293M
$662K 0.01%
17,500
– –
MNKD icon
122
PUT
MannKind Corp
MNKD
$1.21B
$653K 0.01%
90,000
– –
ALIM
123
CALL
DELISTED
Alimera Sciences
ALIM
$484K ﹤0.01%
13,333
– –
XYLO
124
DELISTED
Xylo Technologies
XYLO
$52K ﹤0.01%
375
– –
BAX icon
125
Baxter International
BAX
$12.6B
– –
-319,000
Closed -$10.5M
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2015 Portfolio in Review

As of Q4 2015, OrbiMed held 138 positions worth $11B, up 11% from $9.91B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q4 2015 filing shows 6 new, 33 increased, 26 reduced and 8 closed positions. Its largest new stake was Viatris: 3,157,000 shares worth $171M. The largest sale was Molina Healthcare, an estimated $168M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2015 buy was Viatris: 3,157,000 shares worth $171M.
  • OrbiMed added most to Gilead Sciences in Q4 2015, an estimated $129M increase.
  • OrbiMed's biggest Q4 2015 reduction was Molina Healthcare, cutting an estimated $168M.
  • OrbiMed fully exited Chimerix, Inc. in Q4 2015, selling an estimated $39M.
  • OrbiMed's ten largest holdings make up 40% of its $11B portfolio in Q4 2015.
  • OrbiMed opened 6 new positions and closed 8 in Q4 2015.
  • OrbiMed's portfolio value rose 11% quarter-over-quarter to $11B.

Based on OrbiMed's 13F filing for Q4 2015, filed 16 Feb 2016.